Related Experiment Video

Updated: Oct 14, 2025

Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure
08:20

Simultaneous Application of Transcranial Direct Current Stimulation during Virtual Reality Exposure

Published on: January 18, 2021

4.1K

Comment on-Virtual reality teaching in chemotherapy administration: Randomised controlled trial

Richard Gray1, David R Thompson2, Martin Jones3

  • 1School of Nursing and Midwifery, La Trobe University, Melbourne, Vic., Australia.

Journal of Clinical Nursing
|November 5, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.0K
Virtual Prism Adaptation Therapy: Protocol for Validation in Healthy Adults06:12

Virtual Prism Adaptation Therapy: Protocol for Validation in Healthy Adults

Published on: February 12, 2020

7.0K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
533
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
385